• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, August 5, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

An errant editing enzyme promotes tumor suppressor loss and leukemia propagation

Bioengineer by Bioengineer
January 3, 2019
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: National Institutes of Health


Writing in the January 3 issue of Cancer Cell, researchers at University of California San Diego School of Medicine report that detection of “copy editing” by a stem cell enzyme called ADAR1, which is active in more than 20 tumor types, may provide a kind of molecular radar for early detection of malignancies and represent a new therapeutic target for preventing cancer cell resistance to chemotherapy and radiation.

Adenosine deaminases are a family of three enzymes encoded by the ADAR genes, which stand for adenosine deaminase acting on RNA. They regulate gene expression by modifying nucleotides within double stranded RNA molecules, serving as fundamental editors in the development of new stem cells.

The enzyme, however, is also activated in cancers as diverse as liver, breast and leukemia. A research team led by senior author Catriona Jamieson, MD, PhD, deputy director of the Sanford Stem Cell Clinical Center and deputy director of the UC San Diego Moores Cancer Center, found that the normal functions of the ADAR1 enzyme are hijacked by pre-malignant cells, leading to a cascade of molecular consequences that promote malignant transformation, dormant cancer stem cell generation and resistance to treatment.

“We were able to illuminate the abilities of ADAR1 to ‘hyper-mutate’ tumor suppressor RNAs in leukemia and, at the same time, edit the microRNA aimed at targeting the tumor suppressor RNA. This enzyme turns on cancer resistance via a domino effect on RNA instead of DNA,” said first author Qingfei Jiang, PhD, assistant project scientist in Jamieson’s lab.

Jamieson characterized RNA editing as tweaking basic genetic blueprints, not fundamentally rewriting them. Nonetheless, the results might be dramatic. “One result of detection of malignant RNA editing could be exposing dormant cancer stem cells that often escape therapies that target dividing cells, which leads to therapeutic resistance and disease relapse, and also highlight ADAR as a potentially tractable target for cancer stem cell elimination,” said Jamieson.

###

Co-authors include: Jane Isquith, Maria Anna Zipeto, Raymond Diep, Jessica Pham, Nathan Delos Santos, Eduardo Reynoso, Julisia Chau, Heather Leu, Elisa Lazzari, Wenxue Ma, Sheldon Morris and Frida Holm, UC San Diego and Sanford Consortium for Regenerative Medicine; Etienne Melese, Sanford Consortium and University of British Columbia; Rongxin Fang, Ludwig Institute for Cancer Research and UC San Diego; Mark Minden, Princess Margaret Hospital, Toronto; Bing Ren, Ludwig Institute and UC San Diego and Gabriel Pineda, UC San Diego, Sanford Consortium and National University.

Media Contact
Scott LaFee
[email protected]
858-249-0456

Tags: cancerCell BiologyMedicine/Health
Share12Tweet7Share2ShareShareShare1

Related Posts

Hesperetin Boosts Progesterone Receptors, Lowers ROS

Hesperetin Boosts Progesterone Receptors, Lowers ROS

August 5, 2025
PGK1 Downregulation Hinders Cervical Cancer Growth

PGK1 Downregulation Hinders Cervical Cancer Growth

August 5, 2025

Diosgenin’s Impact on Gastrointestinal Cancer Trends

August 5, 2025

Yonsei University Researchers Create Deep Learning Model to Predict Microsatellite Instability-High Tumors

August 5, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Neuropsychiatric Risks Linked to COVID-19 Revealed

    72 shares
    Share 29 Tweet 18
  • Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    61 shares
    Share 24 Tweet 15
  • Predicting Colorectal Cancer Using Lifestyle Factors

    46 shares
    Share 18 Tweet 12
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Tunable Metafibers Enable Remote 3D Focus Control

Two-Step Lewy Body Detection via Smell and CSF

Bacterial Diversity Across Developmental Stages of Anopheles subpictus

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.